Skip to Content

TOBI Podhaler Approval History

  • FDA approved: Yes (First approved March 22nd, 2013)
  • Brand name: TOBI Podhaler
  • Generic name: tobramycin
  • Dosage form: Inhalation Powder
  • Company: Novartis Pharmaceuticals Corporation
  • Treatment for: Cystic Fibrosis

TOBI Podhaler (tobramycin inhalation powder) is an antibacterial aminoglycoside indicated for the management of cystic fibrosis patients with Pseudomonas aeruginosa.

Development History and FDA Approval Process for TOBI Podhaler

Mar 24, 2013Approval FDA Approves TOBI Podhaler to Treat a Type of Bacterial Lung Infection in Cystic Fibrosis Patients

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.